Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Whitbread Surges On Costa Coffee Sale

Fri, 31st Aug 2018 10:36

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - WINNERS----------Whitbread, up 16%. The hospitality firm said it agreed the sale of its Costa Coffee business to US soft drinks giant Coca-Cola Co at an enterprise value of GBP3.90 billion. Whitbread, which also owns the Premier Inn hotel chain, is expecting net proceeds of GBP3.80 billion, and said most of this will be returned to shareholders. The sale, the company continued, will reduce debt and also allow for an increased pension contribution and further expansion of Premier Inn in both the UK and Germany. Whitbread believes a "substantial" premium would have been created by its planned demerger of Costa Coffee, which was announced in April this year. At the time the company had described itself as "committed" to demerging Costa after the coffee chain saw a decline in annual profit.----------FTSE 100 - LOSERS----------Sage Group, down 6.5%. The accounting software provider said Chief Executive Officer Stephen Kelly has stepped down from his role with immediate effect. He is to "remain available to the group" until May 31, 2019. Kelly has been chief executive of Sage for nearly four years since 2014. The FTSE 100 group has started the process to find a new chief executive. Chief Financial Officer Steve Hare has been given the additional post of chief operating officer on an interim basis, giving him full authority to run the business until a new chief executive is appointed. In addition, Sage said it has continued to trade in line with its full-year guidance of 7.0% organic revenue growth and a 27.5% organic operating margin. The group said achieving this guidance is dependent on the closing of several Enterprise Management opportunities in September.----------Evraz, down 1.5%, Glencore, down 1.2%, BHP Billiton, down 0.9%. The commodity stocks were lower amid concerns that the US-Chinese trade dispute may intensify and over metal tariffs. US President Donald Trump said he could move ahead with a plan to impose tariffs on USD200 billion in Chinese imports as early as next week. In addition, Trump also threatened to pull out from the World Trade Organization and called European trade policies "almost as bad as China," raising fresh worries over trade friction.----------FTSE 250 - WINNERS----------Hays, up 6.4%. Shares in the recruiter were rebounding after it expressed uncertainty for its UK market due to economic instability, despite reporting positive results for its recently ended financial year on Thursday. The stock closed down 4.7% on Thursday. ----------FTSE 250 - LOSERS----------Serco Group, down 3.1%. Exane BNP downgraded the outsourcer to Neutral from Outperform.----------OTHER MAIN MARKET AND AIM - WINNERS----------Midatech Pharma, up 31%. The rare disease-focused pharmaceutical company announced positive data from its proof of concept exploratory study for its key oncology drug candidate MTD201. MTD201 Q-Ocreotide is a sustained-release treatment for carcinoid cancer and acromegaly. In a a double-blind exploratory study, the tolerability, pharmacokinetics and growth hormone profiles after a 30 milligram injection in 24 healthy subjects were compared between MTD201 and Novartis AG's Sandostatin LAR. Results from the study indicated that MTD201 produces a safe sustained-release profile of octreotide with growth hormone levels suppressed by an average of 25%, comparable with Sandostatin. Midatech will now seek regulatory approval for MTD201 as an equivalent product of improved product to Sandostatin in preparation for a follow-on trial.----------OTHER MAIN MARKET AND AIM - LOSERS----------FFI Holdings, down 27%. The entertainment industry contract provider said profit halved as costs associated with its recently listing hurt despite revenue jumping on acquisitions. For the year ended March 31, pretax profit halved to USD5.3 million from USD10.3 million the year prior. This was despite revenue rising to USD58.9 million from USD38.8 million the year before. Profit performance was hurt by a sharp rise in administrative and exceptional costs. Administrative expenses rose to USD29.4 million from USD18.9 million the year prior primarily driven by a jump in staff costs. Exceptional costs also rose to USD10.7 million from USD1.9 million the year before which was chiefly related to USD9.5 million in initial public offering costs.----------
More News
23 Jun 2021 16:09

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
17 Jun 2021 11:43

AIM WINNERS & LOSERS: Midatech Pharma up 90% on Q-Sphera breakthrough

AIM WINNERS & LOSERS: Midatech Pharma up 90% on Q-Sphera breakthrough

Read more
17 Jun 2021 11:05

Breakthrough with Q-Sphera tech sends Midatech Pharma shares up 80%

Breakthrough with Q-Sphera tech sends Midatech Pharma shares up 80%

Read more
30 Apr 2021 16:32

TRADING UPDATES: Asimilar and Worldsec swing to profit

TRADING UPDATES: Asimilar and Worldsec swing to profit

Read more
25 Mar 2021 17:42

IN BRIEF: Midatech Pharma 2020 loss widens; closes Spanish unit

IN BRIEF: Midatech Pharma 2020 loss widens; closes Spanish unit

Read more
26 Jan 2021 19:25

TRADING UPDATES: Manolete Sets Records; Ergomed Earnings Top Forecasts

TRADING UPDATES: Manolete Sets Records; Ergomed Earnings Top Forecasts

Read more
19 Oct 2020 12:52

Midatech reports 'encouraging' results from MTX110 study

(Sharecast News) - Biotechnology company Midatech Pharma announced "encouraging" headline results from a phase 1 study at the University of California, San Francisco (UCSF) in patients with diffuse intrinsic pontine glioma (DIPG) on Monday.

Read more
19 Oct 2020 10:45

Midatech Pharma Encouraged By Phase One Study Results For MTX110

Midatech Pharma Encouraged By Phase One Study Results For MTX110

Read more
19 Oct 2020 10:26

UK WINNERS & LOSERS SUMMARY: boohoo Down 11% As Weekend Press Weighs

UK WINNERS & LOSERS SUMMARY: boohoo Down 11% As Weekend Press Weighs

Read more
10 Sep 2020 14:57

IN BRIEF: Midatech Pharma Loss Widens In First Half On Lower Revenue

IN BRIEF: Midatech Pharma Loss Widens In First Half On Lower Revenue

Read more
3 Sep 2020 16:00

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
19 Aug 2020 11:35

Midatech Pharma Raises USD1 Million From US Warrants Exercise

Midatech Pharma Raises USD1 Million From US Warrants Exercise

Read more
27 Jul 2020 11:25

Midatech raises £5m to fund Q-Sphera development

(Sharecast News) - Drug delivery technology company Midatech Pharma has raised £5m before expenses via a placing to investors in the UK, it announced on Monday, to advance and develop its 'Q-Sphera' products and technology, and for general corporate purposes.

Read more
27 Jul 2020 10:56

Midatech Pharma Placing And Broker Option Raises Almost GBP6 Million

Midatech Pharma Placing And Broker Option Raises Almost GBP6 Million

Read more
24 Jul 2020 17:24

IN BRIEF: Midatech Pharma Terminates Formal Sales Process

IN BRIEF: Midatech Pharma Terminates Formal Sales Process

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.